List of Excipients in Branded Drug HYDROCODONE ACETAMINOPHEN

« Back to Dashboard

Generic Drugs Containing HYDROCODONE ACETAMINOPHEN

Company	Ingredient	NDC	Excipient
RedPharm Drug Inc	hydrocodone, acetaminophen	67296-0016	ALUMINUM OXIDE
RedPharm Drug Inc	hydrocodone, acetaminophen	67296-0016	ANHYDROUS LACTOSE
RedPharm Drug Inc	hydrocodone, acetaminophen	67296-0016	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in HYDROCODONE ACETAMINOPHEN?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE

Hydrocodone Acetaminophen Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Hydrocodone acetaminophen is a mature, genericized Schedule II immediate-release opioid combination. The commercial opportunity is not based on new active-ingredient exclusivity. It is based on reliable manufacturing, differentiated dosage forms, controlled-substance compliance, supply continuity, hospital contracting, and excipient systems that improve manufacturability without creating avoidable regulatory or bioequivalence risk.

The strongest near-term opportunities are low-cost oral solid dosage products, unit-dose hospital packaging, preservative-controlled oral solutions, and contract or private-label supply. Novel abuse-deterrent or modified-release combinations face higher development costs and limited commercial appeal unless supported by a clear clinical or regulatory advantage.

What is hydrocodone acetaminophen and how is it regulated?

Hydrocodone acetaminophen combines hydrocodone, a semisynthetic opioid agonist, with acetaminophen, a non-opioid analgesic. U.S. products are primarily immediate-release tablets, capsules, and oral solutions.

Hydrocodone combination products became Schedule II controlled substances in the United States in October 2014. The change increased prescribing controls, dispensing restrictions, inventory obligations, and compliance costs for manufacturers and distributors (Drug Enforcement Administration, 2014).

Common dosage strengths include:

Hydrocodone / acetaminophen strength	Typical dosage form	Commercial relevance
2.5 mg / 325 mg	Tablet	Lower opioid exposure; limited but differentiated use
5 mg / 300 mg	Tablet or capsule	Older branded and generic strength
5 mg / 325 mg	Tablet, capsule, solution	High-volume generic segment
7.5 mg / 325 mg	Tablet or solution	Established intermediate strength
10 mg / 325 mg	Tablet or capsule	Higher-strength prescription product
Variable concentration	Oral solution	Pediatric, geriatric, and swallowing-related use

The FDA required manufacturers to limit prescription combination products to no more than 325 mg of acetaminophen per dosage unit to reduce the risk of severe liver injury from excessive acetaminophen exposure (U.S. Food and Drug Administration, 2011).

What excipients are used in hydrocodone acetaminophen tablets?

Hydrocodone acetaminophen tablets generally use conventional excipient systems for direct compression or wet granulation. The exact composition varies by manufacturer and approved product.

Typical excipient categories include:

Excipient function	Common options	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Controls tablet weight, compressibility, and content uniformity
Binder	Povidone, copovidone, pregelatinized starch	Improves granule strength and tablet integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports immediate drug release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Controls appearance, swallowability, and product identification
Sweetener or flavor	Sucrose, sorbitol, saccharin, flavor systems	Used mainly in oral solutions
Preservative	Sodium benzoate, parabens, or other permitted systems	Controls microbial growth in aqueous products
pH modifier	Citric acid, sodium citrate, hydrochloric acid, sodium hydroxide	Supports stability, solubility, and preservative effectiveness

The primary formulation challenge is balancing the low dose of hydrocodone against the much larger acetaminophen load. The formulation must achieve content uniformity for hydrocodone while maintaining acceptable tablet hardness, friability, dissolution, and stability.

How should an excipient strategy be designed for generic tablets?

A conventional immediate-release tablet should prioritize low manufacturing risk and robust bioequivalence performance.

Direct-compression strategy

A direct-compression design can reduce processing steps and solvent exposure. Microcrystalline cellulose, a suitable disintegrant, colloidal silicon dioxide, and a low-level lubricant can provide a relatively simple platform.

The risks are segregation, poor flow, and hydrocodone content-uniformity failures. These risks increase when the active ingredients and excipients have materially different particle sizes or densities. Pre-blending, controlled particle-size distribution, and validated blend sampling are important process controls.

Wet-granulation strategy

Wet granulation can improve blend uniformity and tablet robustness, particularly where acetaminophen loading creates poor flow or weak compacts. It adds drying, solvent, processing-time, and residual-moisture considerations.

Acetaminophen can present compression and capping challenges. A granulation system using povidone or pregelatinized starch may improve tablet strength, but excessive binder can slow disintegration and dissolution.

Roller compaction strategy

Roller compaction can reduce water exposure and support continuous or semi-continuous manufacturing. It can also increase tabletability for difficult acetaminophen blends. The main risks are over-compaction, reduced porosity, slower dissolution, and generation of fines.

A roller-compacted product requires tight control of ribbon density, milling, lubrication, and compression force. The process is most attractive where the manufacturer has an established dry-granulation platform.

What excipient choices create the greatest commercial differentiation?

Excipient differentiation has commercial value when it improves product performance, production economics, or patient usability without introducing a new clinical claim.

Abuse-deterrence-oriented excipients

Hydrogel-forming polymers, high-viscosity systems, gelling agents, and crush-resistant matrices can make manipulation more difficult. However, adding these systems to an immediate-release hydrocodone acetaminophen product can alter dissolution, bioequivalence, extractability, and regulatory classification.

A meaningful abuse-deterrent claim generally requires evidence under FDA’s abuse-deterrent opioid guidance. A formulation that is merely harder to crush does not automatically receive abuse-deterrent labeling or commercial recognition (U.S. Food and Drug Administration, 2015).

Low-moisture tablet systems

Low-moisture excipient systems can improve stability and reduce degradation risks during storage. This is particularly relevant for products distributed through high-volume retail and institutional channels.

Silica-based glidants, low-water-content fillers, and protective film coatings can support shelf life, but they must be assessed for dissolution impact and process sensitivity.

Swallowability and patient usability

Film coatings, smaller tablet dimensions, smooth surfaces, and reduced tablet friability can improve administration. These changes are more likely to generate commercial value than complex release-modifying systems because they preserve the immediate-release profile.

Oral solution systems

Oral solutions create opportunities in patients who cannot swallow tablets. The formulation must manage:

• Hydrocodone solubility and chemical stability
• Acetaminophen solubility and precipitation risk
• Palatability
• Preservative efficacy
• Container-closure compatibility
• Dose-measurement accuracy
• Controlled-substance diversion risk

Unit-dose cups, oral syringes, tamper-evident packaging, and calibrated dosing devices can provide commercial differentiation without changing the active ingredients.

What is the FDA and Orange Book status of hydrocodone acetaminophen?

Hydrocodone acetaminophen is an FDA-approved prescription combination with numerous abbreviated new drug applications. The market includes approved generic tablets, capsules, and solutions, along with legacy branded products and discontinued or limited-distribution products.

The FDA Orange Book records approved products, therapeutic-equivalence evaluations, patent certifications, and exclusivity information for listed applications (U.S. Food and Drug Administration, 2024a).

For commercial planning, the relevant regulatory conclusions are:

1. The immediate-release combination is broadly genericized.
2. A product-specific patent analysis must identify the exact reference listed drug and NDA.
3. An old composition of matter patent does not create current protection for the combination.
4. Orange Book-listed patents can differ by dosage form, strength, formulation, or method of use.
5. A generic applicant must address listed patents through Paragraph I, II, III, or IV certification, as applicable.
6. A Paragraph IV notice can trigger litigation and a potential 30-month stay under the Hatch-Waxman framework.

When does hydrocodone acetaminophen lose exclusivity?

The core active ingredients have long passed ordinary small-molecule exclusivity periods. Commercial exclusivity for immediate-release hydrocodone acetaminophen is therefore generally driven by product-specific patents, regulatory exclusivity, manufacturing capability, and supply arrangements rather than by a new chemical entity period.

There is no single expiration date for all hydrocodone acetaminophen products. Expiration depends on:

• The selected reference listed drug
• The specific NDA
• The listed dosage form
• The strength
• Any formulation or method-of-use patents
• Pediatric or other statutory extensions
• Whether the patent remains listed and enforceable

Legacy immediate-release combination products generally present a weaker patent barrier than extended-release hydrocodone products or proprietary abuse-deterrent formulations. Extended-release hydrocodone products such as Hysingla ER and Zohydro ER are separate products and should not be treated as patent-equivalent to immediate-release hydrocodone acetaminophen.

What patent litigation and Paragraph IV risks apply?

Paragraph IV risk is product-specific rather than molecule-wide. A generic hydrocodone acetaminophen applicant may face litigation if the reference product has listed patents covering formulation, dosage form, manufacturing, or method of use.

For a conventional immediate-release tablet, the main legal risks are usually limited to:

• A formulation patent covering a particular excipient matrix
• A tablet coating or physical-property claim
• A specific oral-solution formulation
• A method-of-use patent tied to a labeled indication
• Manufacturing claims that read on a selected process

The strongest design-around strategy is usually to use a conventional excipient platform that does not replicate a proprietary release-control or abuse-deterrent system. A generic applicant must still perform a current Orange Book review and patent certification analysis for its selected reference product.

No broad biosimilar litigation pathway applies because hydrocodone acetaminophen is a small-molecule drug, not a biologic.

What formulations are protected by hydrocodone acetaminophen patents?

Patent protection, where present, is more likely to attach to a specific formulation or product architecture than to the active ingredients themselves.

Potentially protectable features include:

• Modified-release matrices
• Abuse-deterrent polymer systems
• Low-dose high-content uniformity compositions
• Stabilized oral solutions
• Specific preservative systems
• Coatings that alter mechanical or dissolution properties
• Manufacturing processes for granulation or compression
• Combination products with a defined release profile

A conventional immediate-release tablet using standard excipients has limited scope for strong, durable patent differentiation. A formulation patent must also withstand written-description, enablement, obviousness, and infringement challenges.

How strong is the patent estate for hydrocodone acetaminophen?

The patent estate is generally weak for conventional immediate-release generic products and stronger for proprietary extended-release or abuse-deterrent hydrocodone products.

Product category	Patent position	Generic entry risk
Conventional immediate-release tablet	Mature and broadly genericized	High
Conventional capsule	Mature, subject to product-specific listings	High
Oral solution	Potential formulation and stability claims	Moderate
Extended-release hydrocodone without acetaminophen	Product-specific formulation patents may be significant	Moderate to low during patent term
Abuse-deterrent hydrocodone formulation	Potentially stronger formulation estate	Lower during active patent term
New delivery system	Patent-dependent and technically complex	Variable

Patent strength should be evaluated separately from regulatory difficulty. A product can have weak patent protection but still face commercial barriers from Schedule II controls, limited manufacturing slots, DEA quotas, controlled-substance security requirements, and thin margins.

What generic launch scenarios exist?

Low-cost immediate-release tablet

This is the most straightforward opportunity. The product can compete through manufacturing cost, supply reliability, packaging, and wholesaler access. Differentiation is limited, so the commercial model depends on scale and operational execution.

Institutional unit-dose product

Hospitals, ambulatory surgery centers, correctional systems, and government purchasers may value unit-dose blistering, barcoding, tamper-evident packaging, and reliable fill rates. Packaging can provide more practical differentiation than a novel excipient.

Oral solution

An oral solution can target patients with swallowing limitations and institutional settings. It has higher formulation and diversion-control complexity than a tablet, but fewer suppliers may create a more attractive niche.

Authorized or private-label generic

A manufacturer with an approved product can use licensing, co-marketing, or private-label distribution to improve volume utilization. The principal risks are controlled-substance contracting, channel controls, and margin compression.

Specialty formulation

A novel abuse-deterrent or modified-release product could command a higher price, but the development burden includes clinical pharmacokinetics, abuse-deterrence studies, manufacturing validation, and possible patent litigation. The opportunity is substantially narrower than for an ordinary generic.

Which companies are challenging or competing in the market?

Competition is fragmented across large generic manufacturers, specialty pharmaceutical companies, contract manufacturers, and authorized distributors. Relevant competitor groups include:

• Large generic manufacturers with established Schedule II infrastructure
• Specialty opioid companies with proprietary extended-release products
• Hospital-focused suppliers
• Contract development and manufacturing organizations
• Private-label and repackaging companies

The competitive advantage usually comes from DEA-compliant manufacturing capacity, dependable API sourcing, quality-system performance, and distribution relationships. A low-cost formulation alone is unlikely to create durable share.

What licensing deals and manufacturing opportunities exist?

The most practical licensing models include:

1. Finished-dose supply agreements with wholesalers or specialty distributors.
2. Private-label arrangements for hospital and institutional channels.
3. Technology licensing for oral-solution preservation or packaging.
4. Contract manufacturing for companies that hold marketing authorization but lack controlled-substance capacity.
5. Regional commercialization agreements outside the United States.

A licensing transaction should address DEA registration, quota allocation, inventory reconciliation, diversion monitoring, recalls, pharmacovigilance, serialization, and responsibility for regulatory submissions.

Manufacturing IP can be commercially relevant where it lowers solvent use, improves content uniformity, increases batch yield, or reduces tablet defects. Process claims are most valuable when they produce measurable cost or quality advantages and cannot be easily designed around.

What geographic opportunities exist?

The United States is the most structured market because of its large generic infrastructure, FDA approval pathway, Orange Book system, and Schedule II controls. The same formulation cannot be assumed to have identical commercial status in other jurisdictions.

International opportunities depend on:

• Narcotics scheduling
• Import and export permits
• National formularies
• Local opioid restrictions
• Acetaminophen dose limits
• Language and labeling rules
• Local bioequivalence requirements
• Controlled-substance quota systems

Markets with strict opioid controls may favor hospital supply and limited institutional products rather than broad retail distribution.

What is the commercial outlook and revenue exposure?

Hydrocodone acetaminophen is a mature, price-sensitive product. Revenue exposure is highest for manufacturers with:

• High-volume generic contracts
• Limited-source institutional accounts
• Reliable supply during competitor shortages
• Multiple dosage strengths
• Oral-solution capability
• Controlled-substance manufacturing capacity

Revenue risk comes from generic price erosion, opioid-prescribing reductions, regulatory scrutiny, quota restrictions, recalls, and loss of a major wholesaler or group-purchasing contract. Public revenue estimates should be tied to a named manufacturer or product; the active ingredient itself does not have a single consolidated market revenue figure.

The commercial opportunity is strongest where excipient selection supports operational performance. A formulation that improves tablet yield, reduces defects, extends shelf life, or enables a differentiated package can produce more value than a complex excipient system with no regulatory or clinical advantage.

Key Takeaways

• Hydrocodone acetaminophen is a mature genericized Schedule II combination.
• Conventional immediate-release tablets have limited active-ingredient and formulation exclusivity.
• Excipient strategy should focus on content uniformity, compression, dissolution, stability, and cost.
• Oral solutions and institutional unit-dose packaging offer the clearest differentiated niches.
• Abuse-deterrent and modified-release systems may support stronger patents but require higher development and regulatory investment.
• There is no biosimilar risk because the product is a small molecule.
• Paragraph IV exposure depends on the selected reference product and current Orange Book listings.
• The strongest commercial barriers are often controlled-substance compliance, supply reliability, DEA capacity, and distribution access.
• Licensing opportunities are most credible in private-label supply, contract manufacturing, institutional packaging, and regional commercialization.
• Product-specific patent and litigation conclusions require review of the current Orange Book and relevant court records.

FAQs

Can hydrocodone acetaminophen be reformulated with fewer excipients?

Yes. A direct-compression or dry-granulation formulation can reduce the number of excipients, but the design must maintain blend uniformity, tablet strength, dissolution, stability, and bioequivalence.

Is hydrocodone acetaminophen eligible for an over-the-counter switch?

The combination is not an over-the-counter product in the United States. Hydrocodone’s Schedule II status and opioid safety profile create substantial regulatory barriers to nonprescription approval.

Can an oral solution create new patent protection?

Yes, a specific oral-solution composition, preservative system, stability profile, or manufacturing process may support patent claims. Patentability depends on novelty, nonobviousness, enablement, and claim scope.

Does acetaminophen content affect generic approval?

Yes. Acetaminophen content affects labeling, safety, dissolution, content uniformity, and the FDA’s limit of 325 mg per dosage unit for prescription combination products.

Are extended-release hydrocodone products substitutes for hydrocodone acetaminophen?

They are not direct formulation substitutes. Extended-release hydrocodone products have different dosing, pharmacokinetics, labeling, safety considerations, and potentially different patent estates.

References

Drug Enforcement Administration. (2014). Schedules of controlled substances: Rescheduling of hydrocodone combination products from schedule III to schedule II. 79 Fed. Reg. 49661.

U.S. Food and Drug Administration. (2011). FDA drug safety communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. https://www.fda.gov/

U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov/

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2024b). Hydrocodone and acetaminophen prescribing information. https://www.accessdata.fda.gov/-drugsatfda/